1. Home
  2. LOPE vs TGTX Comparison

LOPE vs TGTX Comparison

Compare LOPE & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LOPE

Grand Canyon Education Inc.

HOLD

Current Price

$163.54

Market Cap

4.6B

Sector

Real Estate

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$28.58

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOPE
TGTX
Founded
1949
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.9B
IPO Year
2008
2008

Fundamental Metrics

Financial Performance
Metric
LOPE
TGTX
Price
$163.54
$28.58
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$220.00
$49.80
AVG Volume (30 Days)
283.0K
1.5M
Earning Date
05-21-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
7.71
2.77
Revenue
$511,257,000.00
$2,785,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.99
$25.01
P/E Ratio
$21.11
$10.38
Revenue Growth
N/A
N/A
52 Week Low
$149.37
$25.37
52 Week High
$223.04
$46.48

Technical Indicators

Market Signals
Indicator
LOPE
TGTX
Relative Strength Index (RSI) 49.35 46.17
Support Level $151.84 $27.51
Resistance Level $168.28 $32.77
Average True Range (ATR) 4.64 1.18
MACD 0.63 -0.14
Stochastic Oscillator 67.36 38.84

Price Performance

Historical Comparison
LOPE
TGTX

About LOPE Grand Canyon Education Inc.

Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges both online, on the ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: